WO2023214346 - NOVEL RECOMBINANT AAV VP2 FUSION POLYPEPTIDES
National phase entry:
Publication Number
WO/2023/214346
Publication Date
09.11.2023
International Application No.
PCT/IB2023/054639
International Filing Date
04.05.2023
Title **
[English]
NOVEL RECOMBINANT AAV VP2 FUSION POLYPEPTIDES
[French]
NOUVEAUX POLYPEPTIDES DE FUSION VP2 D'AAV RECOMBINANTS
Applicants **
NOVARTIS AG
Inventors
CIRILLO, Agostino
EBERSBACH, Hilmar
HOSSAIN, Mir
Priority Data
63/364,287
06.05.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3757 | |
| EPO | Filing, Examination, Granting | 19355 | |
| Japan | Filing, Examination, Granting | 2512 | |
| South Korea | Filing, Examination, Granting | 2744 | |
| USA | Filing, Examination, Granting | 12090 |
Total:
40,458
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
This disclosure relates to adeno-associated virus (AAV) VP2 fusion polypeptides comprising an AAV VP2 capsid polypeptide and a polypeptide ligand. The disclosure further relates to rAAV virions comprising such AAV VP2 fusion polypeptides and libraries of nucleic acids encoding such AAV VP2 fusion polypeptides, pharmaceutical compositions comprising such rAAV virions, and related methods and uses.[French]
La présente invention concerne des polypeptides de fusion VP2 de virus adéno-associé (AAV) comprenant un polypeptide de capside VP2 d'AAV et un ligand polypeptidique. L'invention concerne en outre des virions de rAAV comprenant de tels polypeptides de fusion VP2 d'AAV et des banques d'acides nucléiques codant pour de tels polypeptides de fusion VP2 d'AAV, des compositions pharmaceutiques comprenant de tels virions de rAAV, et des procédés et des utilisations associés.